FDAnews
www.fdanews.com/articles/179244-the-medicines-company-discontinues-development-of-mdco-216

The Medicines Company Discontinues Development of MDCO-216

November 11, 2016

The Medicines Company has terminated the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.

Data from the pilot trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development.

View today's stories